Pityriasis Rosea

What is Pityriasis Rosea?
Cause: HHV-6 and HHV-7
The Herald Patch
The Secondary Rash: Christmas Tree Pattern
Atypical Presentations
Diagnosis and Differential
Differentiating from Secondary Syphilis
Treatment Options
Pityriasis Rosea in Pregnancy
Prognosis: What to Expect
Research Papers
Connections
Featured Videos

What is Pityriasis Rosea?

Pityriasis rosea is a common, self-limiting skin rash that resolves on its own within 6–10 weeks in the vast majority of people. It affects roughly 1–2% of the population and is most common in people aged 10–35 years, though it can occur at any age. The name comes from Latin: pityriasis (scaling) and rosea (pink/rose-colored).

Despite its alarming appearance — a widespread rash covering the trunk, arms, and thighs — pityriasis rosea is almost never dangerous in otherwise healthy, non-pregnant individuals. The most important things to understand about it are:

It goes away on its own, typically within 6–8 weeks (range: 4–10 weeks)
It usually does not recur — most people get it only once in their lifetime
It is not contagious in the ordinary sense (mild person-to-person transmission has been proposed but not confirmed)
The main symptom is itching, which ranges from absent to severe; the rash itself is not painful
The critical clinical task is ruling out secondary syphilis, which can look nearly identical

Pityriasis rosea follows a classic two-stage pattern: a single "herald patch" appears 1–2 weeks before the widespread secondary rash erupts. Recognizing the herald patch is the key to early diagnosis.

Cause: HHV-6 and HHV-7

The cause of pityriasis rosea has been debated for over a century, but the strongest evidence points to reactivation of human herpesvirus 6 (HHV-6) and/or human herpesvirus 7 (HHV-7) — two herpesviruses closely related to cytomegalovirus that nearly all adults harbor in a latent state after childhood infection (roseola infantum / exanthem subitum).

Key evidence for the HHV-6/7 hypothesis:

HHV-6 and HHV-7 DNA can be detected in the skin lesions of pityriasis rosea patients
HHV-6/7 virions (viral particles) have been identified within keratinocytes in active lesions by electron microscopy
Serum levels of HHV-6 and HHV-7 are elevated during pityriasis rosea and return to baseline as the rash resolves
Acyclovir (which has activity against HHV-6/7, unlike for herpes simplex) shortens disease course when started early — causally linking the virus to the rash
Cases cluster slightly in spring and fall, consistent with viral epidemiology

This is a reactivation phenomenon, not a new primary infection. The trigger for reactivation in any individual case is rarely identifiable — stress, concurrent illness, or immune fluctuation may play a role. The rash does not represent active herpetic infection in the usual sense; it is an immune-mediated skin response to viral reactivation.

Importantly, certain drugs can cause a pityriasis rosea-like eruption (drug-induced pityriaform exanthem): ACE inhibitors, bismuth, gold, barbiturates, metronidazole, and others. Drug-induced cases tend to be more persistent and resolve when the offending drug is withdrawn.

The Herald Patch

The herald patch (also called the "mother patch" or primary plaque) is the first and most diagnostically important lesion of pityriasis rosea. It appears 1–2 weeks before the generalized rash erupts and has very characteristic features:

Size: Typically 2–5 cm in diameter — distinctly larger than the subsequent secondary lesions
Shape: Oval or round
Color: Salmon-pink to rose-colored
Border: A fine, inward-facing "collarette" of scale at the inner edge of the plaque — scale attached peripherally and trailing inward, creating a collar-like appearance. This trailing scale is distinctive.
Location: Can appear anywhere on the body but most commonly on the trunk, neck, or proximal limbs

The herald patch is often mistaken for tinea corporis (ringworm) at this early stage — both are oval, scaly plaques. The distinction matters because antifungal treatment of "ringworm" that is actually a herald patch will fail, and 1–2 weeks later the patient returns with a dramatically spread rash, now confused and alarmed.

Clinical tip: the trailing scale of the herald patch is directed inward toward the center of the lesion (the free edge of the scale points centrally). In tinea corporis, scale typically points outward at the expanding margin. KOH preparation of the scale from a herald patch will be negative for fungal hyphae; tinea will be positive.

Occasionally the herald patch is absent (in about 20–30% of cases) or so small and transient it was not noticed, causing the generalized rash to appear to erupt without warning.

The Secondary Rash: Christmas Tree Pattern

One to two weeks after the herald patch, a generalized rash erupts over the trunk and proximal limbs — the secondary eruption of pityriasis rosea. Its hallmark is the "Christmas tree" distribution:

Oval or teardrop-shaped pink to salmon papules and patches, each 0.5–2 cm, with a fine trailing collarette of scale similar to (but smaller than) the herald patch
The long axes of the oval lesions align along the skin tension lines (Langer lines) of the trunk — which run obliquely downward and outward from the spine. When viewed from the back, the pattern of lesions forms the silhouette of a fir tree or Christmas tree.
The rash is most dense on the trunk and proximal upper arms and thighs; it spares the face, scalp, palms, and soles (a key distinguishing feature from secondary syphilis, which characteristically involves the palms and soles).
New lesions continue erupting for 1–2 weeks before the rash stabilizes and then begins to fade centrifugally (clearing from the outside in).

Itching is the primary complaint and varies widely: 25–75% of patients report itch, which ranges from mild to severe and disturbing sleep. Heat, sweating, and hot showers typically worsen itching.

Constitutional symptoms (mild fatigue, headache, sore throat, low-grade fever, lymphadenopathy) may precede or accompany the rash in some patients, consistent with a viral reactivation syndrome.

Atypical Presentations

Pityriasis rosea has numerous atypical variants that can complicate diagnosis:

Inverse (reverse) pityriasis rosea: Rash predominantly on axillae, groin, and flexural areas rather than the trunk — the "inverse" distribution. More common in children and in individuals with darker skin tones.
Oral lesions: Present in approximately 16% of patients — erythematous patches, erosions, or hemorrhagic spots on the buccal mucosa or palate. Rarely symptomatic but important to know they occur (can cause diagnostic confusion).
Vesicular (blistering) pityriasis rosea: Vesicles or bullae in addition to typical papules — more common in young children and infants.
Urticarial pityriasis rosea: Wheals rather than papules — rare, may be drug-induced.
Papular pityriasis rosea: Small follicular papules rather than larger oval plaques — more common in children, pregnant women, and individuals with darker skin.
Giant pityriasis rosea: Herald patch exceeds 10 cm; rare.
Recurrent pityriasis rosea: Second episode occurs in roughly 2–3% of patients; those who recur may carry a latent herpesvirus load that allows reactivation more easily.

Diagnosis and Differential

Pityriasis rosea is a clinical diagnosis — there is no specific blood test or biopsy finding that confirms it. Diagnosis rests on recognizing the characteristic morphology and distribution. Skin biopsy (if done) shows non-specific spongiotic dermatitis — useful mainly for ruling out other diagnoses.

Key Differential Diagnoses

Secondary syphilis: The most important and must-not-miss diagnosis — see next section. Always test for syphilis when pityriasis rosea is suspected.
Tinea corporis (ringworm): Herald patch mimicry; KOH preparation negative in pityriasis rosea.
Guttate psoriasis: Small, drop-shaped plaques; scale is silvery and thicker; may follow streptococcal pharyngitis; does not follow skin tension lines.
Nummular eczema: Coin-shaped patches; usually more intensely pruritic; no herald patch; does not follow tension lines.
Drug eruption: Suspect when no herald patch, atypical distribution, prolonged course, recent new medication.
Pityriasis lichenoides chronica: Smaller papules with central adherent scale; chronic course over months to years; no herald patch.

Differentiating from Secondary Syphilis

Secondary syphilis is the single most important condition to exclude when diagnosing pityriasis rosea because the two can be virtually indistinguishable clinically, and untreated secondary syphilis is a serious, infectious systemic disease.

Features That Suggest Secondary Syphilis Over Pityriasis Rosea

Palmar and plantar involvement: Syphilis characteristically involves the palms and soles; pityriasis rosea spares them.
No herald patch: Secondary syphilis does not have a herald patch preceding the eruption.
Condylomata lata: Moist, warty-appearing plaques in intertriginous areas are specific for secondary syphilis.
Mucous patches: Painless oral erosions covered by a gray membrane — more prominent and specific in syphilis than the oral findings of pityriasis rosea.
Lymphadenopathy: More prominent in secondary syphilis, often bilateral, involving epitrochlear nodes (characteristic of syphilis).
History: Preceding painless genital ulcer (primary chancre) 3–12 weeks prior. Sexual history.
Race and risk factors: Syphilis disproportionately affects certain communities; assess risk factors.

RPR Testing

Because the stakes of missing secondary syphilis are high (ongoing infectivity, neurological sequelae, cardiovascular complications), RPR (rapid plasma reagin) testing should be performed on all patients presenting with a rash consistent with pityriasis rosea, particularly when palmar/plantar lesions are present, in sexually active adolescents and young adults, or in any patient with uncertain history. A positive RPR followed by a confirmatory treponemal test (FTA-ABS or TPPA) establishes syphilis. A negative RPR in the right clinical picture makes secondary syphilis very unlikely and supports the pityriasis rosea diagnosis.

Treatment Options

For most patients with pityriasis rosea, reassurance and expectant management are the most important interventions. The rash resolves on its own within 6–10 weeks and does not scar. Explaining this clearly dramatically reduces patient anxiety.

Symptom Relief

Topical corticosteroids (mild to moderate potency): For significant pruritus, a low-to-mid potency topical steroid (hydrocortisone 1%, triamcinolone 0.1%) applied to affected areas reduces itching. Do not use potent steroids over large body surface areas.
Oral antihistamines: Cetirizine, loratadine, or diphenhydramine for itch control, especially at night.
Calamine lotion: Provides topical cooling and mild anti-itch effect; well tolerated.
Emollients: Fragrance-free moisturizers reduce skin barrier disruption and secondary dryness.
Lukewarm (not hot) showers: Hot water dramatically worsens itch; patients should be counseled to switch to lukewarm showers.
Natural sunlight (moderate): Moderate UV exposure may accelerate resolution — a practical consideration since sun exposure is otherwise manageable.

Acyclovir — Antiviral Therapy

The Drago et al. randomized controlled trial (2006) demonstrated that oral acyclovir 800 mg five times daily for 7 days, started within the first week of the rash, significantly shortened the duration of pityriasis rosea and reduced itching compared to placebo. By week 2, 79% of acyclovir-treated patients had complete clearance versus 4% in the placebo group. This remains the best pharmacological evidence for treatment.

Practical considerations for acyclovir use:

Benefit is greatest when started within the first week of the rash appearing; late treatment has diminishing returns
The regimen is 800 mg five times daily (every 4–5 hours while awake) × 7 days — higher dosing than for herpes simplex labialis because acyclovir has less potency against HHV-6/7
Generally well tolerated; nausea and headache are the most common side effects
For patients presenting late (after week 2), or those with mild disease, reassurance alone remains appropriate — acyclovir's effect diminishes substantially after early presentation
Valacyclovir (the prodrug with better bioavailability) has been used by some clinicians at 1,000 mg three times daily, though less studied in PR specifically

Phototherapy

Narrowband UVB (NB-UVB) phototherapy can accelerate resolution of pityriasis rosea and has been used in cases with widespread, severely itchy, or prolonged disease. It requires multiple clinic visits and is generally reserved for cases that are not resolving on schedule or causing significant patient distress.

Pityriasis Rosea in Pregnancy

Pityriasis rosea during pregnancy carries a different risk profile and deserves separate attention. Multiple case series and cohort studies have associated early-onset pityriasis rosea in pregnancy (first 15 weeks of gestation) with adverse outcomes including miscarriage, premature delivery, and rarely neonatal hypotonia.

The proposed mechanism involves HHV-6/7 viremia reaching the fetus during the reactivation episode. The absolute risk is uncertain but real enough to warrant closer monitoring:

Obstetric referral is appropriate for pityriasis rosea in the first trimester
Fetal monitoring (ultrasound) in second trimester cases
Some specialists recommend oral acyclovir to reduce viremia duration in early pregnancy cases, though safety data are limited

Pityriasis rosea developing after 15 weeks of gestation appears to carry lower risk to the fetus. However, any pregnant patient with a new widespread rash should be evaluated promptly to rule out other causes (syphilis, varicella, drug reaction).

Prognosis: What to Expect

The overwhelming majority of patients with pityriasis rosea have an excellent outcome:

Duration: Spontaneous resolution in 4–10 weeks; median ~6 weeks
Recurrence: Only 2–3% of patients experience a second episode
Scarring: The rash does not scar in most patients
Post-inflammatory hyperpigmentation: In individuals with darker skin tones, the cleared rash may leave temporary brown patches (post-inflammatory hyperpigmentation) that fade over weeks to months but can be cosmetically distressing
Itch: For patients with significant pruritus, this is the main quality-of-life impairment during the illness; it resolves with the rash

The most reassuring thing a clinician can offer is accurate information: this rash has a name, a known cause, a predictable course, and it goes away. Most patients who understand this cope well with the temporary cosmetic and symptomatic burden. The anxiety of an undiagnosed widespread rash is often worse than the rash itself.

Research Papers

Key peer-reviewed studies on pityriasis rosea etiology, clinical features, and treatment. Each PMID link opens the study on PubMed.

Drago F, et al. Human herpesvirus 7 in pityriasis rosea. Lancet. 1997;349(9062):1367-1368. PMID 9149709
Drago F, et al. Acyclovir treatment of pityriasis rosea: a double-blind, placebo-controlled clinical trial. J Am Acad Dermatol. 2006;55(1):67-71. PMID 16781295
Drago F, et al. Pityriasis rosea: a comprehensive classification. Dermatology. 2016;232(4):431-437. PMID 27287099
Chuh AA, et al. Evidence-based management of pityriasis rosea. J Eur Acad Dermatol Venereol. 2007;21(1):4-9. PMID 17207161
Broccolo F, et al. Additional evidence that pityriasis rosea is associated with reactivation of human herpesvirus-6 and -7. J Invest Dermatol. 2005;124(6):1234-1240. PMID 15955099
Drago F, et al. Pityriasis rosea and related conditions. Clin Dermatol. 2017;35(2):136-141. PMID 28274355
Mahajan K, et al. Acyclovir in pityriasis rosea: an observer-blind, randomized controlled trial of effectiveness, safety and tolerability. Indian Dermatol Online J. 2015;6(3):181-184. PMID 26009704
Stulberg DL, Wolfrey J. Pityriasis rosea. Am Fam Physician. 2004;69(1):87-91. PMID 14727826
Drago F, et al. Pityriasis rosea in pregnancy: a case series. J Am Acad Dermatol. 2009;61(2):270-272. PMID 19615543
Chuh AA, et al. Pityriasis rosea — an update. Indian J Dermatol Venereol Leprol. 2005;71(5):311-315. PMID 16394429
Eisman S, Sinclair R. Pityriasis rosea. BMJ. 2008;337:a1763. PMID 18957474
Drago F, et al. Human herpesvirus-6 and -7 reactivation and disease recurrence in pityriasis rosea. Australas J Dermatol. 2014;55(3):216-220. PMID 24467654

Curated PubMed topic searches:

Back to Table of Contents

Connections